Dow Jones
34.053,94 -39,02 (-0,11%) Nasdaq
12.200,82 +384,50 (+3,25%) Nikkei 225
27.587,65 +185,60 (+0,68%) EUR/USD
1,0897 -0,0014 (-0,13%) BTC-EUR
21.631,38 -547,04 (-2,47%) CMC Crypto 200
537,74 -7,58 (-1,39%)
Koninklijke Philips N.V. (0LNG.IL)
| Chiusura precedente | 16,05 |
| Aperto | 0,00 |
| Denaro | 0,00 x 0 |
| Lettera | 0,00 x 0 |
| Min-Max giorno | 0,00 - 0,00 |
| Intervallo di 52 settimane | |
| Volume | |
| Media Volume | 3.442.327 |
| Capitalizzazione | 14,727B |
| Beta (5 anni mensile) | 0,79 |
| Rapporto PE (ttm) | 38,85 |
| EPS (ttm) | 0,43 |
| Prossima data utili | N/D |
| Rendimento e dividendo (forward) | 0,85 (5,48%) |
| Data ex dividendo | 12 mag 2022 |
| Stima target 1A | N/D |
- GlobeNewswire
Philips presents its plan to create value with sustainable impact
January 30, 2023 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG; AEX: PHIA), a global leader in health technology, today presents its plan to create value with sustainable impact based on focused organic growth and scalable innovation, with improved execution as the key value driver. Starting at 10:00 am CET, the company will host a webcast with Philips CEO Roy Jakobs, CFO Abhijit Bhattacharya, and other Philips leaders. The presentation slide decks have been published here. Today, Philip
- GlobeNewswire
Philips sees some improvement in Q4 2022 and takes firm actions to address operational challenges in an uncertain environment
January 30, 2023 Fourth-quarter highlights Group sales amounted to EUR 5.4 billion, with 3% comparable sales growth driven by component supply improvements, while Philips’ supply chain conditions remain challengingComparable order intake decreased 8%, due to lower demand for COVID-19-related products compared to 2021 and company actions to improve the order book margin profileIncome from operations amounted to EUR 171 million, compared to EUR 162 million in Q4 2021Adjusted EBITA of EUR 651 milli
- GlobeNewswire
Philips provides update on completed set of test results for first-generation DreamStation sleep therapy devices
December 21, 2022 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG; AEX: PHIA) today provides an update on the comprehensive test and research program of its subsidiary Philips Respironics, following the voluntary recall notification/field safety notice* to address potential health risks related to the polyester-based polyurethane (PE-PUR) sound abatement foam in specific CPAP, BiPAP and mechanical ventilator devices. Following previous updates in December 2021 and June 2022, additional tes
